Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine As a Booster on Participants Previously Administered with OVX836
Phase 2
Active, not recruiting
- Conditions
- Vaccine-Preventable DiseasesInfluenza
- Interventions
- Biological: OVX836 shot
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Osivax
- Target Recruit Count
- 160
- Registration Number
- NCT06582277
- Locations
- 🇧🇪
Centre for Vaccinology (CEVAC) Ghent University Hospital, Ghent, Belgium
First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers
Phase 1
Active, not recruiting
- Conditions
- Coronavirus
- Interventions
- Biological: Saline solutionBiological: OVX033
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Osivax
- Target Recruit Count
- 48
- Registration Number
- NCT06128382
- Locations
- 🇫🇷
CIC Cochin Pasteur CIC 1417 Hôpital Cochin, Paris, France
Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: OVX836 480µgBiological: Afluria QuadBiological: PlaceboBiological: Fluarix Tetra
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Osivax
- Target Recruit Count
- 478
- Registration Number
- NCT05734040
- Locations
- 🇦🇺
Emeritus Research Sydney, Sydney, New South Wales, Australia
🇦🇺CMAX Fusion Clinical Research, Adelaide, South Australia, Australia
🇦🇺Paratus Clinical Research Western Sydney, Sydney, New South Wales, Australia
Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg
Phase 2
Not yet recruiting
- Conditions
- Influenza
- Interventions
- Biological: OVX836 480µgBiological: Saline Solution
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Osivax
- Target Recruit Count
- 1500
- Registration Number
- NCT05569239
Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: OVX836 480µgBiological: Quadrivalent Inactivated Influenza Vaccine (Fluarix® Tetra)Biological: Placebo
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Osivax
- Target Recruit Count
- 180
- Registration Number
- NCT05284799
- Locations
- 🇦🇺
Northern Beaches Clinical Research, Brookvale, New South Wales, Australia
A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness.
Completed
- Conditions
- Influenza
- Interventions
- Other: Blood samples
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Osivax
- Target Recruit Count
- 66
- Registration Number
- NCT05184387
- Locations
- 🇧🇪
Centre for Vaccinology (CEVAC), Ghent, Belgium
Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: OVX836-003Biological: Saline solution
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Osivax
- Target Recruit Count
- 239
- Registration Number
- NCT05060887
- Locations
- 🇧🇪
Centre for Vaccinology (CEVAC), Ghent, Belgium
Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: OVX836Biological: Quadrivalent seasonal influenza vaccine (Influvac TetraTM)
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Osivax
- Target Recruit Count
- 300
- Registration Number
- NCT04192500
- Locations
- 🇧🇪
Centre for Vaccinology (CEVAC), Ghent, Belgium
Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Biological: Placebo (Intramuscular)Biological: OVX836 (Intranasal)Biological: OVX836 (Intramuscular)Biological: Placebo (Intranasal)
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Osivax
- Target Recruit Count
- 72
- Registration Number
- NCT03594890
- Locations
- 🇧🇪
Centre for the Evaluation of Vaccination, University of Antwerp, Antwerpen, Belgium
© Copyright 2025. All Rights Reserved by MedPath